Document:

EX-10.1

 Exhibit 10.1 
  

 
 March 17, 2019 
 Raymond
Silcock 
 Dear Ray, 
 I would like to formally congratulate
you on becoming a part of the Perrigo family and an integral part of my leadership team that will transform Perrigo to a world class consumer focused self-care company over the next few years! For more than 130 years, Perrigo has provided high
quality, affordable self-care products to families around the world and there is no greater reward than helping make lives better. 
 Perrigo sets the
standard for hiring top talent, which is why I’m so pleased to confirm in writing the offer you and I agreed upon for the Executive Vice President & Chief Financial Officer position, reporting to me and to give you the opportunity to
help over 10,000 passionate Perrigo employees around the globe bring our vision to a reality: 
 To make lives better by bringing quality, affordable
self-care products that consumers trust everywhere they are sold. 
 This offer is contingent upon successful completion of a pre-employment drug test, a background check, and your ability to legally work in the United States. We are targeting a start date of March 25th, 2019. 

The base salary for this position will be $650,000 annually (paid over 24 pay periods on the 15th and last day of each month). 

Other terms of our offer also include: 
  

	•	 	 A sign on bonus in the gross amount of $500,000. If you voluntarily leave employment with Perrigo for any reason
within the first 12 months of employment, you will be responsible to repay 66% of your sign on bonus. If you voluntarily leave employment with Perrigo for any reason within months 13-24 of employment, you will
be responsible to repay 50% of your sign on bonus. 

  

	•	 	 Participation in Perrigo’s Annual Incentive Plan (AIP) plan. The AIP is a cash bonus plan. Your target
annual payout for the bonus is 80% of base salary. Bonus payouts take place following the end of the calendar year, with payout occurring in mid-February. Your first payout in February/March of 2020
will be pro-rated based upon your start date. The Corporate AIP program is funded based on company performance consistent with the other executive officers including myself and is a combination of
Revenues (30%) and Operating Income (50%) on our core consumer businesses; there is also an individual performance factor based on strategic objectives (20%) which you and I will set together once you arrive. 

 

	•	 	 Eligibility to receive equity through Perrigo’s discretionary Long-Term Incentive (LTI) Plan. Perrigo grants
equity using a combination of Performance-based Restricted Stock Units (PSUs) and Service-based Restricted Stock Units (RSUs). You will receive your initial discretionary LTI award in full for 2019 shortly after you join and which is described
in the next paragraph. LTI awards are generally made following the start of the calendar/fiscal year in February or March. Your 2020 and subsequent annual targeted equity award will be $2,000,000. This grant will consist of 50% OI (Operating
Income)-PSUs, 20% rTSR (relative Total Shareholder Return)-PSUs, and 30% ratable Service-based RSUs. Receipt of the Equity Award is subject to the terms outlined in your Equity Award grant agreement and Perrigo’s 2013 Long-Term Incentive Plan
(and any amendments, modifications or successor documents) including retirement eligibility treatment at age 65. 

  

	•	 	 Your 2019 award will be an allocation of equity equal to $2,000,000 which will be granted on the 5th trading day
of the month following your start date and is subject to performance objectives. This grant will have the same construct as the annual grant in terms of split between 50% OI (PSU’s), 20% rTSR (PSU’s), and 30% ratable Service based-RSU’s. Receipt of the Equity Award is subject to the terms outlined in your Equity Award grant agreement and Perrigo’s 2013 Long-Term Incentive Plan (and any amendments, modifications or successor
documents) including retirement eligibility treatment at age 65. 

  

	•	 	 As a member of our senior executive team, you will be eligible to participate in the Perrigo Non-Qualified Deferred Compensation (NQDC) Plan. 

 

 
  

	•	 	 Eligibility for a performance and salary review on April
1st, 2020 and annually thereafter. Your increase may be pro-rated based on your start date. 

 

	•	 	 Eligibility to participate in our health and welfare benefits to include: health, dental, prescription, and life
insurance, 401(k), profit sharing retirement, tuition reimbursement and paid holidays and vacation. 

 Please refer to the attached
Perrigo Employee Benefit Guide for a full description of all of the benefits you are eligible to receive. 
  

	•	 	 Eligibility to participate in the Perrigo Company Executive Committee Severance Policy, the Perrigo Company U.S.
Severance Policy, and the Perrigo Company Change In Control Severance Policy for U.S. Employees pursuant to the terms and conditions of each policy, copies of each are attached. 

 

	•	 	 Your eligibility to participate in the various benefit plans refrenced above is governed by the terms and
conditions of each plan document, and you, as with any other executive officer, are subject to any plan design changes made by the Remuneration Committee or the Board of Directors. 

 

	•	 	 Immediately begin earning and receiving vacation at a rate of 6.66 hours per pay period (annual equivalent of 160
hours or 4 weeks) and may begin using time as it is earned or carry it over in accordance with company policy. 

  

	•	 	 Your primary work location will be Allegan, Michigan. You will be responsible for all associated commuting costs
to and from Michigan. 

  

	•	 	 We understand your desire is to maintain your residency in California and commute to Michigan on a regular basis.
Please be advised, by working in the State of Michigan, Perrigo will be required to withhold certain taxes and other withholdings. We advise you to seek counsel from your personal tax advisor on how to manage your state income tax withholdings and
reconcile between California and Michigan. 

 We hold the highest standard for our products, as well as for our employees. Our employees
adhere to three Core Values: Integrity – “We do what is right”, Respect — “We demonstrate the value we hold for one another” and Responsibility – “We hold ourselves
accountable for our actions.” These Core Values are at the heart of our corporate culture and a vital part of our success today. 
 Please be sure
to review the Perrigo Employee Handbook enclosed with this letter. It outlines key policies and the expectations we have for our employees. A copy of our Code of Conduct, which outlines additional policies, will also be included among other online
training and will be discussed during your orientation. 
 Perrigo is an at-will employer, meaning that either you
or Perrigo are free to end the employment relationship at any time, with or without notice or cause. Nothing in this letter or in Perrigo’s policies or procedures, either now or in the future, are intended to change the at-will nature of our relationship. 
 Again, we are very excited that you will be joining the Perrigo family. The role
you play will be key to our overall success, especially given the expertise and background you will bring to Perrigo. On behalf of the leadership team, congratulations and welcome to Perrigo! 

 

 
  

 Should you have any questions about the details of this offer, please feel free to call me. 

 

							
	Sincerely,	 		 		 	
			
	PERRIGO COMPANY	 		 	ACKNOWLEDGEMENT
			
	/s/ Murray Kessler	 		 	/s/ Raymond Silcock
	Murray Kessler	 		 	Raymond Silcock
	President & CEO	 		 	DATE	 	3/17/2019EX-4.17

 EXHIBIT 4.17 

NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY
INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF
SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, MAY BE SOLD OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. 

Warrant No.              

GALECTIN THERAPEUTICS, INC. 

COMMON STOCK PURCHASE WARRANT 

Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), for value received and subject to the terms set forth below
hereby grants to             , or its registered successors and assigns (the “Holder”), the right to purchase from the Company at any time or from time to time until the date and
time permitted under Section 2.1 below, [•] ([•]) fully paid and nonassessable shares of the Company’s Common Stock, par value $0.001 per share, at the purchase price of [•] ($[•]) per share (the “Exercise
Price”). The Exercise Price and the number and character of such shares of Common Stock purchasable pursuant to the rights granted under this Warrant are subject to adjustment as provided herein. 

1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Subscription Agreement. As used
herein the following terms, unless the context otherwise requires, have the following respective meanings: 
 “Common
Stock” means the Company’s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter have been reclassified or changed into, including any stock (other than Common
Stock) and other securities of the Company or any other Person (corporate or other) which the Holder of this Warrant at any time shall be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to
Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock pursuant to Section 3.2 hereof or otherwise. 

“Common Stock Equivalents” means any securities of the Company or its subsidiaries which would entitle the
holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles
the holder thereof to receive, Common Stock. 
 “Issue Date” means
            , 201    . 
 “Market
Value” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market (other than the OTC Bulletin Board), the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based on a Trading Day from 9:30 a.m. Eastern Time to
4:00 p.m. Eastern Time); (b) if the Common Stock is then listed or quoted on the OTC Bulletin Board, the average of the high and low price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; or
(c) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported in the “Pink Sheets” published by the Pink Sheets, LLC (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent bid price per share of the Common Stock so reported. 

  
 1 

 “Subscription Agreement” means the Non-Transferable
Subscription Rights Certificate pursuant to which the original Holder exercised its right to purchase units consisting of 0.3 shares of Common Stock and a warrant to purchase 0.075 shares of Common Stock under a Stockholder Rights Offering of the
Company. 
 “This Warrant” means, collectively, this Warrant and all other stock purchase warrants issued in
exchange therefor or replacement thereof. 
 “Trading Day” means a day on which the common Stock is traded
on a Trading Market. 
 “Trading Market” means any of the following markets or exchanges on which the common
Stock is listed or quoted for trading on the date in question: the Nasdaq SmallCap Market, the NYSE Alternext US, the New York Stock Exchange, the Nasdaq National Market, the OTC Bulletin Board or the “Pink Sheets”. 

2. Exercise. 
 2.1 Exercise Period. The Holder
may exercise this Warrant at any time after the Issue Date and before 5:00 P.M. New York City Time on the seventh (7th) anniversary of the Issue Date (the “Exercise Period”), unless
earlier terminated pursuant to Section 3.2 herein. 
 2.2 Exercise Procedure. 

(a) This Warrant will be deemed to have been exercised at such time as the Company has received all of the following items (the “Exercise
Date”): 
 (i) a completed Exercise Notice as described in Section 2.4 hereof, executed by the Person exercising
all or part of the purchase rights represented by this Warrant (the “Purchaser”); 
 (ii) this Warrant; 

(iii) if this Warrant is not registered in the name of the Purchaser, an Assignment or Assignments in the form set forth in
Exhibit B hereto, evidencing the assignment of this Warrant to the Purchaser together with any documentation required pursuant to Section 7 hereof; and 

(iv) a check payable to the order of the Company in an amount equal to the product of the Exercise Price multiplied by the
number of shares of Common Stock being purchased upon such exercise. 
 (b) As soon as practicable after the exercise of this Warrant in full
or in part, and in any event within ten (10) days after the Exercise Date, the Company at its expense will cause to be issued in the name of and delivered to the Purchaser, or as the Purchaser (upon payment by the Purchaser of any applicable
transfer taxes) may direct, a certificate or certificates for the number of fully paid and non-assessable shares of Common Stock to which the Purchaser shall be entitled upon such exercise, together with any other stock or other securities and
property (including cash, where applicable) to which the Purchaser is entitled upon exercise. 
 (c) Unless this Warrant has expired or all
of the purchase rights represented hereby have been exercised, the Company at its expense will, within ten (10) days after the Exercise Date, issue and deliver to or upon the order of the Purchaser a new Warrant or Warrants of like tenor, in
the name of the Purchaser or as the Purchaser (upon payment by the Purchaser of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock remaining issuable under this
Warrant. 
 (d) The Common Stock issuable upon the exercise of this Warrant will be deemed to have been issued to the Purchaser on the
Exercise Date, and the Purchaser will be deemed for all purposes to have become the record holder of such Common Stock on the Exercise Date. 

  
 2 

 (e) The issuance of certificates for shares of Common Stock upon exercise of this Warrant
will be made without charge to the Holder or the Purchaser for any issuance tax in respect thereof or any other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock. 

(f) The holder represents and warrants that at the time of any exercise of this warrant the holder is an “accredited investor,” as
such term is defined in Rule 501 promulgated under the Securities Act and acknowledges and agrees that the Company may, in its sole discretion, (i) require, as a condition to the exercise of this Warrant, that the holder provide such written
evidence that such holder is an accredited investor as the time of exercise, and (ii) decline to issue the shares of Common Stock issuable upon such exercise if the Company is not satisfied that this warrant may be exercised by the holder
pursuant to a valid registration exemption from the Securities Act and any applicable state securities law. 
 2.3 Acknowledgement of
Continuing Obligations. The Company will, at the time of the exercise of this Warrant, upon the request of the Purchaser, acknowledge in writing its continuing obligation to afford to the Purchaser any rights to which the Purchaser shall continue to
be entitled after such exercise in accordance with the provisions of this Warrant, provided that if the Purchaser shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to the Purchaser
any such rights. 
 2.4 Exercise Notice. The Exercise Notice will be substantially in the form set forth in Exhibit A
hereto, except that if the shares of Common Stock issuable upon exercise of this Warrant are not to be issued in the name of the Purchaser, the Exercise Notice will also state the name of the Person to whom the certificates for the shares of Common
Stock are to be issued, and if the number of shares of Common Stock to be issued does not include all the shares of Common Stock issuable hereunder, it will also state the name of the Person to whom a new Warrant for the unexercised portion of the
rights hereunder is to be delivered.  
 2.5 Fractional Shares. If a fractional share of Common Stock would, but for the provisions
of Section 2.1 hereof, be issuable upon exercise of the rights represented by this Warrant, the Company will, within ten (10) days after the Exercise Date, deliver to the Purchaser a check payable to the Purchaser in lieu of such
fractional share, in an amount equal to the Market Value of such fractional share as of the close of business on the Exercise Date. 
 3. Adjustments. 

3.1 Adjustments for Stock Splits, Etc. If the Company shall at any time after the Issue Date subdivide its outstanding Common Stock, by
split-up or otherwise, or combine its outstanding Common Stock, or issue additional shares of its capital stock in payment of a stock dividend in respect of its Common Stock, the number of shares issuable on the exercise of the unexercised portion
of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Exercise Price then applicable to shares covered by the unexercised
portion of this Warrant shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or proportionately increased in the case of combination. 

3.2 Adjustment for Reclassification, Reorganization, Etc. In case of any reclassification, capital reorganization, or change of the
outstanding Common Stock (other than as a result of a subdivision, combination or stock dividend), or in the case of any consolidation of the Company with, or merger of the Company into, another Person (other than a consolidation or merger in which
the Company is the continuing corporation and which does not result in any reclassification or change of the outstanding Common Stock of the Company), or in case of any sale or conveyance to one or more Persons of the property of the Company as an
entirety or substantially as an entirety at any time prior to the expiration of this Warrant, then, as a condition of such reclassification, reorganization, change, consolidation, merger, sale or conveyance, lawful provision shall be made, and duly
executed documents evidencing the same from the Company or its successor shall be delivered to the Holder of this Warrant, so that the Holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a
total price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, the kind and amount of shares of stock and other securities and property receivable upon such reclassification, reorganization, change,
consolidation, merger, sale or conveyance by a holder of the number of shares of Common Stock of the Company as to which this Warrant was exercisable immediately prior to such reclassification, reorganization, change, consolidation, merger, sale or
conveyance, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for the adjustment of the
Exercise Price and of the number of shares 

  
 3 

 
purchasable upon exercise of this Warrant) shall thereafter be applicable in relation to any shares of stock, and other securities and property, thereafter deliverable upon exercise hereof. If,
as a consequence of any such transaction, solely cash, and no securities or other property of any kind, is deliverable upon exercise of this Warrant, then, in such event, the Company may terminate this Warrant by giving the Holder hereof written
notice thereof. Such notice shall specify the date (at least thirty (30) days subsequent to the date on which notice is given) on which, at 3:00 P.M., Norcross, Georgia time, this Warrant shall terminate. Notwithstanding any such notice, this
Warrant shall remain exercisable, and otherwise in full force and effect, until such time of termination. 
 3.3 Certificate of Adjustment.
Whenever the Exercise Price or the number of shares issuable hereunder is adjusted, as herein provided, the Company shall promptly deliver to the registered Holder of this Warrant a certificate of the Treasurer of the Company, which certificate
shall state (i) the Exercise Price and the number of shares of Common Stock issuable hereunder after such adjustment, (ii) the facts requiring such adjustment, and (iii) the method of calculation for such adjustment and increase or
decrease. 
 3.4 Small Adjustments. No adjustment in the Exercise Price shall be required unless such adjustment would require
an increase or decrease in the Exercise Price of at least one percent; provided, however, that any adjustments which by reason of this Section 3.4 are not required to be made immediately shall be carried forward and taken into account at the
time of exercise of this Warrant or any subsequent adjustment in the Exercise Price which, singly or in combination with any adjustment carried forward, is required to be made under Sections 3.1 or 3.2. 

4. Reservation of Stock, etc., Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely for issuance and
delivery upon the exercise of this Warrant, all shares of Common Stock from time to time issuable upon the exercise of this Warrant. 
 5. Disposition of
This Warrant, Common Stock, Etc. The Holder of this Warrant and any transferee hereof or of the Common Stock with respect to which this Warrant may be exercisable, by their acceptance hereof, hereby understand and agree that this Warrant has not
been registered under the Securities Act, and may not be sold, pledged, hypothecated, donated, or otherwise transferred (whether or not for consideration) without an effective registration statement under the Act or an opinion of counsel
satisfactory to the Company and/or submission to the Company of such other evidence as may be satisfactory to counsel to the Company, in each such case, to the effect that any such transfer shall not be in violation of the Act. It shall be a
condition to the transfer of this Warrant that any transferee thereof deliver to the Company its written agreement to accept and be bound by all of the terms and conditions of this Warrant. The foregoing notwithstanding, the Company acknowledges
that the shares of Common Stock to be issued upon the exercise of this Warrant have been registered under the Securities Act. 
 6. Rights and Obligations
of Warrant Holder. The Holder of this Warrant shall not, by virtue hereof, be entitled to any voting rights or other rights as a stockholder of the Company. No provision of this Warrant, in the absence of affirmative actions by the Holder to
purchase Common Stock of the Company by exercising this Warrant, and no enumeration in this Warrant of the rights or privileges of the Holder, will give rise to any liability of such Holder for the Exercise Price of Common Stock acquirable by
exercise hereof or as a stockholder of the Company. 
 7. Transfer of Warrants. Subject to compliance with the restrictions on transfer applicable to
this Warrant referred to in Section 5 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, without charge to the registered Holder, upon surrender of this Warrant with a properly executed Assignment (in
substantially the form attached hereto as Exhibit B), to the Company, and the Company at its expense will issue and deliver to or upon the order of the Holder hereof a new Warrant or Warrants in such denomination or denominations as
may be requested, but otherwise of like tenor, in the name of the Holder or as the Holder (upon payment of any applicable transfer taxes) may direct. 
 8.
Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon delivery of an indemnity
agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like
tenor. 
 9. Company Records. Until this Warrant is transferred on the books of the Company, the Company may treat the registered Holder hereof as
the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 

  
 4 

 10. Miscellaneous. 

10.1 Notices. All notices and other communications from the Company to the Holder of this Warrant shall be mailed by first class mail, postage prepaid, to
such address as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and at the address of the last Holder of this Warrant who has so furnished an address to the Company. All communications from
the Holder of this Warrant to the Company shall be mailed by first class mail, postage prepaid, to Galectin Therapeutics, Inc., 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, Attn: 

Chief Financial Officer, or such other address as may have been furnished to the Holder in writing by the Company. 

10.2 Amendment and Waiver. Except as otherwise provided herein, this Warrant and any term hereof may be amended, waived, discharged or terminated only by an
instrument in writing signed by the party against which enforcement of such amendment, waiver, discharge or termination is sought. 
 10.3 Governing Law;
Descriptive Headings. This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Delaware. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of
the terms hereof. 
 [SIGNATURE ON FOLLOWING PAGE] 

  
 5 

 Dated:             , 2019. 

 

			
	 GALECTIN THERAPEUTICS, INC.

		
	By:	 	          

	Name:	 	
	Title:	 	

  
 6 

 EXHIBIT A 

EXERCISE NOTICE 
 [To be signed
only upon exercise of Warrant] 

To:                          
                                         
                                     Date: 

The undersigned, the Holder of the within Warrant, pursuant to the provisions set forth in the within Warrant, hereby irrevocably elects to
exercise the purchase rights represented by such Warrant for, and agrees to subscribe for and purchase thereunder,             shares of the Common Stock covered by such Warrant and
herewith makes payment of $             therefor, and requests that the certificates for such shares be issued in the name of, and delivered
to,             , whose address is:             . If said number of shares is less than all the shares covered by such Warrant, a
new Warrant shall be registered in the name of the undersigned and delivered to the address stated below. 
  

			
	Signature	 	  

		
		 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant or on the form of Assignment attached as Exhibit B thereto.)
		
	Address	 	  

		
		 	  

		
	[Signature Guarantee]	 	

  
 7 

 EXHIBIT B 

ASSIGNMENT 
 [To be signed only
upon transfer of Warrant] 
 For value received, the undersigned hereby sells, assigns and transfers all of the rights of the undersigned
under the within Warrant with respect to the number of shares of the Common Stock covered thereby set forth below, unto: 
  

					
	Name of Assignee	  	Address	  	No. of Shares

  

							
	Dated:	 		 	Signature	 	
				
		 		 		 	 (Signature must conform in all respects to name of

Holder as specified on the face of the Warrant.)

				
		 		 	Address	 	
			
		 		 	[Signature Guarantee]

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]